Cited by 318Inhalation and Respiratory Drug DeliveryTuberculosis Research and EpidemiologyAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

Pandey, Rajesh, Khuller, G.K.·2005·Tuberculosis

DOI 10.1016/j.tube.2004.11.003

Open this paper in CoChat — free account

Abstract

The present study was planned to evaluate the chemotherapeutic potential of nebulized solid lipid particles (SLPs) incorporating rifampicin, isoniazid and pyrazinamide against experimental tuberculosis. The SLPs prepared by the "emulsion solvent diffusion" technique possessed a favourable mass median aerodynamic diameter suitable for bronchoalveolar drug delivery. Following a single nebulization to guinea pigs, therapeutic drug concentrations were maintained in the plasma for 5 days and in the organs (lungs, liver and spleen) for 7 days whereas free drugs were cleared by 1-2 days. The mean residence time and drug bioavailability were improved several-fold in the case of drug-loaded SLPs. A similar pharmacokinetic profile was observed in Mycobacterium tuberculosis-infected guinea pigs. On nebulization of drug-loaded SLPs to infected guinea pigs at every 7th day, no tubercle bacilli could be detected in the lungs/spleen after 7 doses of treatment whereas 46 daily doses of orally administered drugs were required to obtain an equivalent therapeutic benefit. Further, there was no evidence of any biochemical hepatotoxicity. Thus, nebulization of SLP-based antitubercular drugs forms a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis.

Integrity signals

Registry

Crossref · 10.1016/j.tube.2004.11.003

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

THIS ARTICLE HAS BEEN RETRACTEDï¿½ï¿½Aerosolised liposomal hamycin for treatment of systemic Candida infections in mice
Dhuley, J. N. (1999) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.1999.tb01347.x · Cited by 4
Retracted
Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. D. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 1,008
Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization
Schwarz, C., Mehnert, W., Lucks, J. S., & Müller, R. H. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90047-7 · Cited by 574
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 389
Self-citation
Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization
Hu, F., Yuan, H., Zhang, H. H., & Fang, M. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00081-9 · Cited by 284
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis
Pandey, R., Zahoor, A., Sharma, S., & Khuller, G. K. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.07.001 · Cited by 220
Self-citation
Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
Videira, M. A., Botelho, M. F., Santos, A. C., Gouveia, L. F., Pedroso de Lima, J. J., & Almeida, A. J. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000054933 · Cited by 213
Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201
Solid lipid nanoparticles (SLN) for controlled drug delivery
Müller, R. H., Freitas, C., Mühlen, A. Z., & Mehnert, W. (1996) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(97)86243-4 · Cited by 174
Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization
Jenning, V., Lippacher, A., & Gohla, S. (2002) · Journal of Microencapsulation · doi:10.1080/713817583 · Cited by 163

Show all 24 references

Research works printed but not linked: 1

Scott, 1967, Fluorimetric determination of isonicotinic acid hydrazide in plasma, J Lab Clin Med, 70, 355

Sorted by citations

“Nanoantibiotics”: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,920
Drug delivery systems: An updated review
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671
Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,288
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K. H., Smith, B. J., Lee, J. H., Yavlovich, A., Heldman, E., & Blumenthal, R. P. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,099
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904
Solid lipid nanoparticles as a drug delivery system for peptides and proteins☆
Almeida, A. J., & Souto, E. B. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.007 · Cited by 817
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S. E., Kisich, K. O., Iseman, M. D., & Heifets, L. B. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 744
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art
Weber, S., Zimmer, A., & Pardeike, J. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.08.013 · Cited by 579
Nanoparticles: Emerging carriers for drug delivery
Mudshinge, S. R., Deore, A. B., Patil, S. R., & Bhalgat, C. M. (2011) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2011.04.001 · Cited by 557
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.
Üner, M., & Yener, G. (2007) · PubMed Central · Cited by 536
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Nanomedicine in pulmonary delivery
Mansour, H. M., Haemosu, & Wu, X. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s4937 · Cited by 497
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440
Nanostructured lipid carriers system: Recent advances in drug delivery
Iqbal, M. A., Md, S., Sahni, J. K., Baboota, S., Dang, S., & Ali, J. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.716845 · Cited by 459
Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections
Abed, N., & Couvreur, P. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.009 · Cited by 365
The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases
Nisini, R., Poerio, N., Mariotti, S., Santis, F. D., & Fraziano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00155 · Cited by 308
Oral solid lipid nanoparticle-based antitubercular chemotherapy
Pandey, R., Sharma, S., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2005.08.009 · Cited by 271
Self-citation
Antituberculosis drugs and hepatotoxicity
Yew, W. W., & Leung, C. C. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00941.x · Cited by 263
Targeted Intracellular Delivery of Antituberculosis Drugs to Mycobacterium tuberculosis-Infected Macrophages via Functionalized Mesoporous Silica Nanoparticles
Clemens, D. L., Lee, B.-Y., Xue, M., Thomas, C. R., Meng, H., Ferris, D., Nel, A. E., Zink, J. I., & Horwitz, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06049-11 · Cited by 260
Solid lipid nanoparticles for pulmonary delivery of insulin
Liu, J., Gong, T., Fu, H., Wang, C., Wang, X., Chen, Q., Zhang, Q., He, Q., & Zhang, Z. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.01.008 · Cited by 249
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.020 · Cited by 245
Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery
Yoon, G., Park, J. W., & Yoon, I. (2013) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-013-0087-y · Cited by 224
Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application
Pardeike, J., Weber, S., Haber, T., Wagner, J., Zarfl, H. P., Plank, H., & Zimmer, A. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.040 · Cited by 216
Tuberculosis chemotherapy: current drug delivery approaches
du Toit, L. C., Pillay, V., & Danckwerts, M. P. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-118 · Cited by 213
Lipid Nanoparticles: Effect on Bioavailability and Pharmacokinetic Changes
Souto, E. B., & Müller, R. H. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00477-3_4 · Cited by 217
Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications
Garud, A., Singh, D., & Garud, N. (2012) · International Current Pharmaceutical Journal · doi:10.3329/icpj.v1i11.12065 · Cited by 203
Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer
Yassin, A. E. B., Anwer, M. K., Mowafy, H. A., Elbagory, I., Bayomi, M. A., & Alsarra, I. A. (2010) · International Journal of Medical Sciences · doi:10.7150/ijms.7.398 · Cited by 188
Antitubercular inhaled therapy: opportunities, progress and challenges
Pandey, R., & Khuller, G. K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki027 · Cited by 188
Self-citation
Pulmonary drug delivery systems for tuberculosis treatment
Pham, D.-D., Fattal, E., & Tsapis, N. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.12.009 · Cited by 185
Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development
Attama, A. A., Momoh, M. A., & Uzor, P. F. (2012) · InTech eBooks · doi:10.5772/50486 · Cited by 181
One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis
Ohashi, K., Kabasawa, T., Ozeki, T., & Okada, H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.027 · Cited by 178
Nanotechnology-Based Approach in Tuberculosis Treatment
Nasiruddin, M., Neyaz, M. K., & Das, S. (2017) · Tuberculosis Research and Treatment · doi:10.1155/2017/4920209 · Cited by 177
Inhalable microparticles containing large payload of anti-tuberculosis drugs
Muttil, P., Kaur, J. P., Kumar, K., Yadav, A. B., Sharma, R., & Misra, A. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.06.006 · Cited by 173
Inhaled drug therapy for treatment of tuberculosis
Misra, A., Hickey, A. J., Rossi, C. R., Borchard, G., Terada, H., Makino, K., Fourie, P. B., & Colombo, P. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.08.009 · Cited by 174
Nanobead-based interventions for the treatment and prevention of tuberculosis
Griffiths, G., Nyström, B., Sable, S. B., & Khuller, G. K. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2437 · Cited by 169
Self-citation
Gelatin nanocarriers as potential vectors for effective management of tuberculosis
Saraogi, G. K., Gupta, P., Gupta, U. D., Jain, N. K., & Agrawal, G. P. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.10.004 · Cited by 156
Inhaled Drug Delivery for Tuberculosis Therapy
Muttil, P., Wang, C., & Hickey, A. J. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9957-4 · Cited by 148
Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer
Bakhtiary, Z., Barar, J., Aghanejad, A., Saei, A. A., Nemati, E., Ezzati, A., & Omidi, Y. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1310223 · Cited by 139
Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies
Gaspar, D. P., Faria, V., Gonçalves, L., Taboada, P., Remuñán‐López, C., & Almeida, A. J. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.11.050 · Cited by 136
Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy
Nemati, E., Mokhtarzadeh, A., Panahi‐Azar, V., Mohammadi, A., Hamishehkar, H., Abbasi, M. M., Ezzati, A., & de la Guárdia, M. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1334-y · Cited by 134
Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery
Rajpoot, K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190903155321 · Cited by 130
Lipid-Based Nanoparticles for Drug-Delivery Systems
Kumar, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814033-8.00008-4 · Cited by 128
The formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123
Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans
Cipolla, D. C., Shekunov, B. Y., Blanchard, J., & Hickey, A. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.001 · Cited by 123
Biodegradable nanoparticles for intracellular delivery of antimicrobial agents
Xie, S., Tao, Y., Pan, Y., Qu, W., Cheng, G., Huang, L., Chen, D., Wang, X., Liu, Z., & Yuan, Z. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.034 · Cited by 129
Lipid-based nanoformulations for peptide delivery
Matougui, N., Boge, L., Groo, A., Umerska, A. M., Ringstad, L., Bysell, H., & Saulnier, P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.019 · Cited by 119
Respirable nanocarriers as a promising strategy for antitubercular drug delivery
Mehanna, M. M., Mohyeldin, S. M., & Elgindy, N. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.038 · Cited by 119
Solid Lipid Nanoparticles: Applications and Prospects in Cancer Treatment
Sivadasan, D., Ramakrishnan, K., Mahendran, J., Ranganathan, H., Karuppaiah, A., & Rahman, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076199 · Cited by 117
Montelukast-loaded nanostructured lipid carriers: Part I Oral bioavailability improvement
Patil-Gadhe, A., & Pokharkar, V. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.05.019 · Cited by 107
Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles
Chuan, J., Li, Y., Yang, L., Sun, X., Zhang, Q., Gong, T., & Zhang, Z. (2013) · Journal of Nanoparticle Research · doi:10.1007/s11051-013-1634-1 · Cited by 107
Tuberculosis pharmacotherapy: strategies to optimize patient care
Mitnick, C. D., McGee, B., & Peloquin, C. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802694564 · Cited by 103
Solid lipid microparticles as an approach to drug delivery
Scalia, S., Young, P. M., & Traini, D. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.980812 · Cited by 102
Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Qi, J., Lü, Y., & Wu, W. (2012) · Current Drug Metabolism · doi:10.2174/138920012800166526 · Cited by 98
Lipid Nanocarriers-Enabled Delivery of Antibiotics and Antimicrobial Adjuvants to Overcome Bacterial Biofilms
Ahsan, A., Thomas, N., Barnes, T. J., Subramaniam, S., Loh, T. C., Joyce, P., & Prestidge, C. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030396 · Cited by 105
Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice
Verma, R. K., Kaur, J. P., Kumar, K., Yadav, A. B., & Misra, A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00153-08 · Cited by 96
Nano-technology for targeted drug delivery to combat antibiotic resistance
Sharma, A., Arya, D. K., Dua, M., Chhatwal, G. S., & Johri, A. K. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.717927 · Cited by 94
Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra
Sharma, R., Muttil, P., Yadav, A. B., Rath, S. K., Bajpai, V. K., Mani, U., & Misra, A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl533 · Cited by 94
Chitosan coated nanostructured lipid carriers (NLCs) for loading Vitamin D: A physical stability study
Rabelo, R. S., de Oliveira, I. F., da Silva, V. M., Prata, A. S., & Hubinger, M. D. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.174 · Cited by 93
Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches
Dua, K., Rapalli, V. K., Shukla, S. D., Singhvi, G., Shastri, M. D., Chellappan, D. K., Satija, S., Mehta, M., Gulati, M., Pinto, T. D. J. A., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.101 · Cited by 92
Nanostructured drug delivery for better management of tuberculosis
Kaur, I. P., & Singh, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.009 · Cited by 89
Delivery of antibiotics to the respiratory tract: an update
Traini, D., & Young, P. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903110710 · Cited by 86
Montelukast-loaded nanostructured lipid carriers: Part II Pulmonary drug delivery and in vitro–in vivo aerosol performance
Patil-Gadhe, A., Kyadarkunte, A., Patole, M., & Pokharkar, V. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.07.007 · Cited by 84
Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties
Ma, C., Wu, M., Ye, W., Huang, Z., Ma, X., Wang, W., Wang, W., Huang, Y., Pan, X., & Wu, C. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00849-7 · Cited by 84
Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis
Baranyai, Z., Soria‐Carrera, H., Alleva, M., Millán-Placer, A. C., Lucía, A., Martín‐Rapún, R., Aínsa, J. A., & de la Fuente, J. M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000113 · Cited by 86
Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis
Maretti, E., Rossi, T., Bondi, M., Croce, M. A., Hanuskovà, M., Leo, E., Sacchetti, F., & Iannuccelli, V. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.12.034 · Cited by 85
Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: Preparation, characterization and in vivo evaluation
Zhao, Y. J., Chang, Y., Hu, X., Liu, C., Quan, L., & Liao, Y. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.11.046 · Cited by 84
Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities
Patil, K. D., Bagade, S. B., Bonde, S., Sharma, S., & Saraogi, G. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.115 · Cited by 83
Single step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach
Patil-Gadhe, A., & Pokharkar, V. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.07.006 · Cited by 83
Inhaled drug treatment for tuberculosis: Past progress and future prospects
Hickey, A. J., Durham, P. G., Dharmadhikari, A., & Nardell, E. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.018 · Cited by 81
Nanoparticle delivery of grape seed-derived proanthocyanidins to airway epithelial cells dampens oxidative stress and inflammation
Castellani, S., Trapani, A., Spagnoletta, A., di Toma, L., Magrone, T., Gioia, S. D., Mandracchia, D., TRAPANI, G., Jirillo, E., & Conese, M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1509-4 · Cited by 83
Nanoparticle based Drug Delivery Systems for Treatment of Infectious Diseases
Salouti, M., & Ahangari, A. (2014) · InTech eBooks · doi:10.5772/58423 · Cited by 78
Lipid-based carriers: manufacturing and applications for pulmonary route
Jaafar‐Maalej, C., Elaı̈ssari, A., & Fessi, H. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.702751 · Cited by 77
Solid Lipid Nanoparticles: An Approach to Improve Oral Drug Delivery
Mendoza‐Muñoz, N., Urbán‐Morlán, Z., Leyva‐Gómez, G., Zambrano‐Zaragoza, M. L., Piñón‐Segundo, E., & Quintanar‐Guerrero, D. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31788 · Cited by 77
Smart Drug Delivery System
Sezer, A. D. (2016) · InTech eBooks · doi:10.5772/60475 · Cited by 78
In vitro evaluation of inhalable isoniazid‐loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis
Chimote, G., & Banerjee, R. (2010) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.31608 · Cited by 75
Overview of nano-drugs characteristics for clinical application: the journey from the entry to the exit point
Bose, T., Latawiec, D., Mondal, P. P., & Mandal, S. (2014) · Journal of Nanoparticle Research · doi:10.1007/s11051-014-2527-7 · Cited by 71
The Future for Early-Stage Tuberculosis Drug Discovery
Zuniga, E. S., Early, J. V., & Parish, T. (2015) · Future Microbiology · doi:10.2217/fmb.14.125 · Cited by 71
Nano-scale delivery: A comprehensive review of nano-structured devices, preparative techniques, site-specificity designs, biomedical applications, commercial products, and references to safety, cellular uptake, and organ toxicity
Abdellatif, A. A. H., Mohammed, H. A., Khan, R. A., Singh, V., Bouazzaoui, A., Yusuf, M., Akhtar, N., Khan, M., Al-Subaiyel, A., Mohammed, S. A. A., et al. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0096 · Cited by 76
Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons
Pardeike, J., Weber, S., Zarfl, H. P., Pagitz, M., & Zimmer, A. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.07.018 · Cited by 68
Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs
Garcia‐Contreras, L., Sung, J. C., Ibrahim, M., Elbert, K. J., Edwards, D. A., & Hickey, A. J. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00046 · Cited by 67
Nanomedicine and experimental tuberculosis: facts, flaws, and future
Pandey, R., & Ahmad, Z. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.01.009 · Cited by 66
Self-citation
Passive lung-targeted drug delivery systems via intravenous administration
Wei, Y., & Zhao, L. (2013) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2012.757782 · Cited by 66
Improved antimycobacterial activity of rifampin using solid lipid nanoparticles
Aboutaleb, E., Noori, M., Gandomi, N., Atyabi, F., Fazeli, M. R., Jamalifar, H., & Dinarvand, R. (2012) · International nano letters. · doi:10.1186/2228-5326-2-33 · Cited by 66
Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety
El-Ridy, M. S., Yehia, S. A., Kassem, M. A., Mostafa, D. M., Nasr, E. A., & Asfour, M. H. (2013) · Drug Delivery · doi:10.3109/10717544.2013.868556 · Cited by 64
Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review
Buya, A. B., Witika, B. A., Bapolisi, A. M., Mwila, C., Mukubwa, G. K., Memvanga, P. B., Makoni, P. A., & Nkanga, C. I. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122041 · Cited by 70
Solid lipid nanoparticles for drug delivery
Harms, M., & Müller-Goymann, C. C. (2011) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(11)50008-5 · Cited by 61
Nanoparticle formulations for therapeutic delivery, pathogen imaging and theranostic applications in bacterial infections
Jiang, L., Ding, L., & Liu, G. (2023) · Theranostics · doi:10.7150/thno.82790 · Cited by 65
Preparation of glyceryl monostearate-based particles by PGSS®—Application to caffeine
de Sousa, A. R. S., Simplı́cio, A. L., de Sousa, H. C., & Duarte, C. M. M. (2007) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2007.03.015 · Cited by 59
A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats
Haque, S., Whittaker, M. R., McIntosh, M. P., Pouton, C. W., Phipps, S., & Kaminskas, L. M. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.01.001 · Cited by 58
Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections
Gaspar, M. M., Cruz, A., Fraga, A. G., Castro, A. G., Cruz, M. E. M., & Pedrosa, J. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783955629 · Cited by 58
Nanoparticulate devices for brain drug delivery
Celia, C., Cosco, D., Paolino, D., & Fresta, M. (2010) · Medicinal Research Reviews · doi:10.1002/med.20201 · Cited by 58
Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis
Chae, J., Choi, Y., Tanaka, M., & Choi, J. H. (2021) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2021.08.009 · Cited by 56
Nanotechnology based drug delivery system(s) for the management of tuberculosis.
Pandey, R., & Khuller, G. K. (2006) · PubMed · Cited by 56
Self-citation
A review of emerging trends in the treatment of tuberculosis
Kaur, M., Garg, T., & Narang, R. K. (2014) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2014.962745 · Cited by 54
Advances in nanotechnology for diagnosis and treatment of tuberculosis
Banyal, S., Malik, P., Tuli, H. S., & Mukherjee, T. K. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32835eff08 · Cited by 53
The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy
Mortensen, N. P., Durham, P., & Hickey, A. J. (2014) · Journal of Microencapsulation · doi:10.3109/02652048.2014.932029 · Cited by 52
Assessment of lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the lung
Shilpi, S., Vimal, V. D., & Soni, V. (2015) · Progress in Biomaterials · doi:10.1007/s40204-015-0037-z · Cited by 52
Current status and future prospects for new therapies for pulmonary tuberculosis
Souza, M. V. N. D. (2006) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000219264.42686.c9 · Cited by 52

Authors: Pandey, R., & Khuller, G. K.
Affiliations: Post Graduate Institute of Medical Education and Research (IN)
Corresponding author: Khuller, G.K.
ORCID: Pandey, Rajesh
Venue: Tuberculosis
Publisher: Elsevier BV
Published: 2005-07
Volume: 85
Issue: 4
Pages: 227-234
ISSN: 1472-9792 (ISSN-L)
DOI: 10.1016/j.tube.2004.11.003
OpenAlex: W2137397041
Cited by: 318
References: 24
Citations by year: 2026: 5 · 2025: 12 · 2024: 9 · 2023: 13 · 2022: 17 · 2021: 21 · 2020: 18 · 2019: 19 · 2018: 24 · 2017: 18 · 2016: 24 · 2015: 13 · 2014: 26 · 2013: 20 · 2012: 14
FWCI: 7.42
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Tuberculosis (publishedVersion)
PubMed (publishedVersion)
Funders: Department of Science and Technology, Ministry of Science and Technology, India
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: solid lipid particles, pulmonary tuberculosis, nebulized drug delivery, rifampicin, isoniazid, pyrazinamide, antitubercular agents, emulsion solvent diffusion, aerosol drug delivery, pharmacokinetics, drug bioavailability, Mycobacterium tuberculosis, guinea pig model, hepatotoxicity
MeSH terms: Administration, Inhalation, Animals, Antitubercular Agents, Biological Availability, Drug Carriers, Guinea Pigs, Isoniazid, Lipids, Pyrazinamide, Rifampin, Tuberculosis, Drug Delivery Systems, Area Under Curve, Nanostructures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks